Dietary Flavonoids in the Management of Huntington’s Disease: Mechanism and Clinical Perspective
- Materials Science
This research presents a meta-analyses of the phytochemical properties of cannabis and its application in medicine and its role in human health, as well as some examples of applications in food safety and nutrition.
Role of Dynein Axonemal Heavy Chain 6 Gene Expression as a Possible Biomarker for Huntington’s Disease: a Translational Study
- BiologyJournal of Molecular Neuroscience
Downregulations in dynein family are confirmed in the mouse model and decreased expression of DNAH6 gene was also observed in HD patients when compared to control group and negatively correlates with the CAG expansion.
SHOWING 1-10 OF 234 REFERENCES
Accurate prevalence and uptake of testing for Huntington's disease
- MedicineThe Lancet Neurology
Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features
- Biology, ChemistryJournal of neurochemistry
J. Neurochem. (2010) 113, 1073–1091.
- Medicine, PsychologyNeurology
Your contributions to the investigation of this tragic disorder are presented and a review of current ideas about the disease is reviewed.
The current clinical management of Huntington's disease
- Psychology, MedicineMovement disorders : official journal of the Movement Disorder Society
The pharmacological management of the various movement disorders associated with Huntington's disease, the cognitive decline and the commonly encountered behavioral disturbances are reviewed.
Altered frontostriatal coupling in pre‐manifest Huntington’s disease: effects of increasing cognitive load
- Medicine, PsychologyEuropean journal of neurology
The objective of this study was to test the impact of cognitive demand on prefrontal connectivity in pre‐HD individuals.
Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
- Medicine, PsychologyMovement disorders : official journal of the Movement Disorder Society
Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way, however, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial.
Apathy is not depression in Huntington's disease.
- Psychology, MedicineThe Journal of neuropsychiatry and clinical neurosciences
It is found that apathy and depression are not related and are clearly distinct dimensions, whereas depression was not.
Psychopathology in Huntington's disease patients
- Psychology, MedicineActa psychiatrica Scandinavica
A retrospective study of 30 Huntington's disease families showed the minimum lifetime prevalence of depression to be 39% in the prodrome and the diagnosed disease phase of the illness, and the frequency of symptomatic schizophrenia was found to be about 9%.
Huntington’s Disease: What We Learned From the Original Essay
- MedicineThe neurologist
Accurate descriptions before and after Huntington’s essay about hereditary chorea have provided humanity to sufferers and the nidus for new discovery within the field of movement disorders.
Olanzapine for Huntington's disease: An open label study
- Medicine, PsychologyEuropean Neuropsychopharmacology